Vagus Nerve Stimulation for Knee Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether stimulating a nerve in the ear can reduce knee pain and improve body functions in individuals with knee osteoarthritis. Researchers aim to determine if this method, known as transcutaneous vagus nerve stimulation (tVNS), is easy to use and affects pain perception and bodily response. Participants will undergo a 60-minute treatment and complete various assessments to measure changes in pain and satisfaction. The trial seeks individuals who have experienced knee pain for at least 3 months that worsens with activity and who can speak English. As an unphased trial, this study offers participants the chance to contribute to innovative research that could lead to new pain management solutions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this transcutaneous vagus nerve stimulation is safe for knee osteoarthritis?
Research has shown that using a device on the ear to stimulate a nerve, known as transcutaneous vagus nerve stimulation (tVNS), might safely treat knee osteoarthritis. Early results suggest that tVNS can reduce pain without causing serious side effects. In studies, participants generally tolerated it well, experiencing few side effects. Those who used tVNS on their ears reported less pain and improved movement. So far, tVNS appears to be a promising and safe option for managing knee pain.12345
Why are researchers excited about this trial?
Transcutaneous vagus nerve stimulation (tVNS) is unique because it offers a non-invasive approach to managing knee osteoarthritis pain. Unlike standard treatments like NSAIDs or corticosteroid injections, tVNS targets the vagus nerve at the ear, potentially modulating pain signals and reducing inflammation without the need for medications. Researchers are excited about this method because it may provide relief with fewer side effects and risks, making it an innovative option for people seeking alternatives to traditional therapies.
What evidence suggests that transcutaneous vagus nerve stimulation is effective for knee osteoarthritis?
Research has shown that transcutaneous vagus nerve stimulation (tVNS) can reduce pain in individuals with knee osteoarthritis (OA). Studies have found that tVNS decreases knee sensitivity to pain, resulting in less discomfort for patients. Early data suggest that tVNS not only alleviates knee pain but also offers a safe treatment option. These findings indicate that tVNS might ease pain and improve autonomic functions like heart rate. Overall, early results are promising for tVNS as a treatment for knee OA pain.12346
Are You a Good Fit for This Trial?
This trial is for adults over 45 with chronic knee pain from osteoarthritis, experiencing an average pain intensity of 4 or higher on a scale of 0 to 10. Participants should have had this pain for at least three months and be able to communicate in English.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete self-reported questionnaires and baseline assessments of knee pain severity, central pain sensitivity, and heart rate variability.
tVNS Intervention
Participants receive a 60-minute transcutaneous vagus nerve stimulation (tVNS) session at the cymba concha of the left ear.
Post-Intervention Assessment
Investigators assess changes in knee pain, central pain sensitivity, and autonomic function immediately after and 15 minutes after tVNS intervention.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including satisfaction level and safety assessment.
What Are the Treatments Tested in This Trial?
Interventions
- Transcutaneous vagus nerve stimulation
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas, El Paso
Lead Sponsor